Pediatric Vaccine Expansion FDA-expanded indication for CAPVAXIVE to children and teens with chronic conditions increases the pediatric market for Merck's pneumococcal vaccine. This creates opportunities to collaborate with hospitals, vaccination programs, and payer networks to drive uptake, support education campaigns, and align with pediatric care pathways.

Animal Health Growth Merck Animal Health is pursuing growth in the canine dermatology space, highlighted by a global survey about canine pruritus and challenges in treatment. This suggests a path for rapid-onset dermatology therapies with veterinarians and pet owners, including veterinary clinics, distributors, and pet insurers, and potential cross-pollination with human health franchises in family health settings.

AI Discovery Partnerships Merck's collaboration with Protillion Biosciences on AI-driven multi-target drug discovery indicates a strategy to leverage external platforms for faster candidate generation. This opens doors for co-development or licensing deals with biotech startups and academic groups, and for building a robust external-innovation funnel.

Digital Operations Merck's tech stack—Azure Data Explorer and UiPath—signals a data-driven, automated operating model. Sales opportunities exist for data analytics, AI and automation tools, or digitalization services to optimize R&D planning, manufacturing throughput, and supply chain resilience across a global pharma footprint.

Strategic Partnerships With a substantial global footprint and a diversified pipeline, Merck appears open to strategic partnerships, licensing, and contract services to support growth. Potential sales angles include co-development in vaccines or biologics, contract manufacturing partnerships, and regional expansion initiatives.